NASDAQ:MRNA

Moderna Competitors

$139.40
-1.52 (-1.08 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$136.36
Now: $139.40
$143.49
50-Day Range
$118.49
MA: $139.26
$174.74
52-Week Range
$31.71
Now: $139.40
$189.26
Volume6.05 million shs
Average Volume11.65 million shs
Market Capitalization$55.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.73

Competitors

Moderna (NASDAQ:MRNA) Vs. AMGN, GILD, BIIB, BNTX, SGEN, and TECH

Should you be buying MRNA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Moderna, including Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), BioNTech (BNTX), Seagen (SGEN), and Bio-Techne (TECH).

Moderna (NASDAQ:MRNA) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Amgen0101402.58

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.21%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than Amgen.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Moderna and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Amgen29.42%95.55%15.52%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
Amgen$23.36 billion6.14$7.84 billion$14.8216.80

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Moderna on 10 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Gilead Sciences191402.54

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Gilead Sciences has a consensus price target of $97.2308, suggesting a potential upside of 50.37%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Moderna and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Gilead Sciences5.48%37.77%12.76%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
Gilead Sciences$22.45 billion3.63$5.39 billion$6.1410.53

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Moderna on 11 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Biogen5141202.23

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Biogen has a consensus price target of $303.5862, suggesting a potential upside of 15.52%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Moderna and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Biogen35.63%51.00%23.54%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
Biogen$14.38 billion2.78$5.89 billion$33.577.83

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Moderna on 10 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and BioNTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
BioNTech04302.43

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. BioNTech has a consensus price target of $105.50, suggesting a potential downside of 13.18%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than BioNTech.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500.

Profitability

This table compares Moderna and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
BioNTech-250.12%-66.72%-41.73%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 10.8% of BioNTech shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and BioNTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
BioNTech$121.63 million240.57$-200,540,000.00($0.95)-127.92

BioNTech has higher revenue and earnings than Moderna. BioNTech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Summary

Moderna beats BioNTech on 9 of the 14 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Seagen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Seagen161112.63

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Seagen has a consensus price target of $185.3571, suggesting a potential upside of 31.72%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Moderna.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares Moderna and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Seagen25.34%20.46%16.67%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Seagen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
Seagen$916.71 million27.83$-158,650,000.00($1.33)-105.80

Seagen has higher revenue and earnings than Moderna. Seagen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Moderna on 13 of the 15 factors compared between the two stocks.

Moderna (NASDAQ:MRNA) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Bio-Techne, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna36902.33
Bio-Techne03702.70

Moderna presently has a consensus price target of $149.6471, suggesting a potential upside of 7.35%. Bio-Techne has a consensus price target of $367.50, suggesting a potential downside of 8.82%. Given Moderna's higher possible upside, equities analysts plainly believe Moderna is more favorable than Bio-Techne.

Risk & Volatility

Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares Moderna and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-242.73%-28.11%-20.31%
Bio-Techne32.69%12.20%8.09%

Institutional and Insider Ownership

51.2% of Moderna shares are held by institutional investors. Comparatively, 93.8% of Bio-Techne shares are held by institutional investors. 29.2% of Moderna shares are held by insiders. Comparatively, 3.8% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Moderna and Bio-Techne's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million927.31$-514,020,000.00($1.55)-89.94
Bio-Techne$738.69 million21.17$229.30 million$3.86104.42

Bio-Techne has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Moderna on 9 of the 14 factors compared between the two stocks.

pixel
Ad TAAT MGMT
The Tobacco Industry Change is Here!
big tobacco executives have shied away from the product and are turning to this stock!

Moderna Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.94-0.0%$143.34 billion$23.36 billion20.08
Gilead Sciences logo
GILD
Gilead Sciences
2.8$64.66-0.7%$81.41 billion$22.45 billion66.66
Biogen logo
BIIB
Biogen
1.9$262.80-2.0%$40.03 billion$14.38 billion8.70Analyst Report
BioNTech logo
BNTX
BioNTech
0.9$121.52-0.5%$29.26 billion$121.63 million-60.76Analyst Revision
Seagen logo
SGEN
Seagen
1.7$140.72-1.5%$25.51 billion$916.71 million55.40Insider Selling
Bio-Techne logo
TECH
Bio-Techne
2.0$403.05-1.4%$15.64 billion$738.69 million64.49
argenx logo
ARGX
argenx
1.3$263.25-5.6%$13.51 billion$78.17 million-55.66Analyst Upgrade
Novavax logo
NVAX
Novavax
1.6$175.65-2.3%$12.97 billion$18.66 million-33.65
QIAGEN logo
QGEN
QIAGEN
1.5$51.58-0.6%$11.76 billion$1.53 billion63.68Analyst Downgrade
Repligen logo
RGEN
Repligen
1.5$207.02-0.4%$11.34 billion$270.24 million252.46Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.79-0.6%$8.72 billion$788.10 million99.78Analyst Downgrade
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$114.39-1.2%$8.63 billion$289.59 million-35.09
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$123.08-3.1%$7.45 billion$73.99 million-47.52
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$75.00-4.0%$7.03 billion$10.68 million-40.76Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$129.01-2.5%$6.28 billion$90.10 million-34.40Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.95-0.4%$6.15 billion$195.99 million268.44
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$50.30-3.9%$6.09 billion$26.68 million-22.76News Coverage
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.17-0.6%$5.59 billion$85.07 million-42.28Insider Selling
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.12-0.0%$5.52 billion$8.09 million-18.27Gap Down
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$106.20-2.7%$5.43 billionN/A-45.78
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.52-0.4%$4.66 billion$503.70 million33.11
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$29.41-2.7%$4.32 billionN/A-15.32News Coverage
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$68.82-2.0%$4.30 billion$20,000.00-4.90
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$29.58-11.0%$4.16 billionN/A-13.89Analyst Report
News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$67.45-2.2%$3.30 billionN/A-38.76
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$69.04-1.9%$3.08 billion$125.57 million-40.37
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.77-2.6%$2.96 billionN/A0.00
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.25-8.7%$2.88 billion$50.04 million0.00Insider Selling
News Coverage
Vericel logo
VCEL
Vericel
1.1$58.18-0.7%$2.68 billion$117.85 million-5,818,000.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.51-0.1%$2.66 billion$20.53 million-22.71Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.94-8.2%$1.95 billion$31.43 million-4.75News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$27.98-0.6%$1.88 billion$44.67 million-2.55
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$22.26-7.3%$1.81 billionN/A-10.40
NantKwest logo
NK
NantKwest
1.3$16.09-4.8%$1.76 billion$40,000.00-22.66
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.50-7.5%$1.69 billion$48.83 million-12.50
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.06-0.4%$1.59 billion$102.43 million-18.43Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.03-2.4%$1.58 billionN/A-47.99News Coverage
Immunovant logo
IMVT
Immunovant
1.8$15.27-2.7%$1.50 billionN/A-11.84
AlloVir logo
ALVR
AlloVir
1.4$22.76-2.0%$1.48 billionN/A0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$33.75-4.2%$1.43 billion$35.23 million-13.61
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$31.43-6.4%$1.41 billionN/A0.00Insider Selling
Replimune Group logo
REPL
Replimune Group
1.5$29.35-2.5%$1.36 billionN/A-16.58News Coverage
Alector logo
ALEC
Alector
1.3$16.80-3.4%$1.34 billion$21.22 million-7.53
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$30.71-6.3%$1.32 billionN/A0.00News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$17.12-0.8%$1.29 billion$7.80 million-16.00
Ocugen logo
OCGN
Ocugen
1.1$6.68-4.2%$1.26 billionN/A-4.51
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.70-0.5%$1.15 billionN/A-2.97
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.29-2.2%$1.12 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.45-0.7%$1.10 billion$32.16 million-9.60
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.16-0.3%$1.03 billionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.